Many women with breast cancer could avoid chemotherapy — what you need to know about the genetic test - Down To Earth

Groundbreaking genomic assays, spearheaded by Veracyte Prosigna test, are now routinely sparing tens of thousands more early-stage, hormone receptor-positive breast cancer patients from the debilitating side effects of chemotherapy. Recent clinical guideline updates, reflecting robust long-term data, solidify these tests as a critical tool, ensuring treatment de-escalation without compromising efficacy for those with favorable recurrence score. This marks a significant shift in oncology, moving aggressively towards truly personalized medicine. This momentum builds on over a decade of research into molecular subtyping, following earlier breakthroughs like Exact Sciences' Oncotype DX. For patients with HR-positive, HER2-negative breast cancer and no lymph node involvement, or minimal nodal positivity, these tests analyze gene expression to predict the likelihood of recurrence and the benefit of chemotherapy. The latest data, including findings presented at ASCO 2026, demonstrate superior stratification capabilities for tests like Prosigna, allowing clinicians to confidently identify ultra-low-risk patients who gain no additional survival benefit from cytotoxic regimens, sparing them from neuropathy, fatigue, and hair loss. The expanded adoption and reimbursement coverage for these advanced genomic test are set to reshape treatment pathways globally, with healthcare systems prioritizing cost-effectiveness and patient quality of life. Future research will likely focus on extending these de-escalation strategies to more complex cases and other cancer types, further embedding personalized medicine at the core of oncological care. Patients and providers alike are now empowered with unprecedented clarity, signaling a hopeful future for breast cancer management.